| Ms Tanya Helmstetler, MSW, LICSW | |
|
1010 2nd Ave S, Fargo, ND 58103-8226 | |
| (701) 239-6801 | |
| (701) 241-5775 |
| Full Name | Ms Tanya Helmstetler |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 1010 2nd Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205256203 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 2583 (North Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Tanya Helmstetler, MSW, LICSW 1010 2nd Ave S, Fargo, ND 58103-8226 Ph: (701) 239-6801 | Ms Tanya Helmstetler, MSW, LICSW 1010 2nd Ave S, Fargo, ND 58103-8226 Ph: (701) 239-6801 |
News Archive
A new study published on the preprint server bioRxiv reports the elucidation of the mechanism of inhibition of SARS-CoV-2 by a non-nucleotide inhibitor called suramin. This is the first such compound to be shown to have such activity and shows promise for use as a repurposed drug against COVID-19.
Sen. John Rockefeller, the Senate Finance Committee's number two Democrat, said Tuesday that he will not support Sen. Max Baucus' health reform bill "in its present form." Meanwhile, Senate Majority Leader Harry Reid plans to open debate on the bill by the end of September.
Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
› Verified 3 days ago
Rachel Marsolek, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 721 1st Ave N, Fargo, ND 58102 Phone: 701-461-7364 | |
Brittany Joy Alexander, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2101 Elm St N, Fargo, ND 58102 Phone: 701-232-3241 | |
Tracy E Mohn, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 100 4th St S, Fargo, ND 58103 Phone: 701-234-3106 Fax: 701-234-3106 | |
Rachel Salquist, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2101 Elm St N, Fargo, ND 58102 Phone: 701-232-3241 | |
Tracy M Foldesi-penas, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 100 4th St S, Fargo, ND 58103 Phone: 701-234-3100 Fax: 701-234-3120 | |
Lindsey Leigh Krueger, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 6046 14th St S, Fargo, ND 58104 Phone: 701-404-0997 Fax: 701-566-8876 | |
Deonne J Varriano, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2624 9th Ave S, Fargo, ND 58103 Phone: 701-298-4500 Fax: 701-298-4400 |